Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils
H Lin, KM Boesel, DT Griffith, C Prussin, B Foster… - Journal of allergy and …, 2004 - Elsevier
BACKGROUND: Omalizumab is a monoclonal anti-IgE antibody that is effective for the
treatment of allergic respiratory disorders; however, its onset of action is unknown.
OBJECTIVE: This study was designed to determine the onset of action of omalizumab
through the use of a challenge model to determine time-dependent inhibition of ragweed-
induced changes in nasal volume as well as correlate the kinetics of omalizumab-induced
decreases in serum free IgE and FcεRI receptors on basophils. METHODS: We conducted a …
treatment of allergic respiratory disorders; however, its onset of action is unknown.
OBJECTIVE: This study was designed to determine the onset of action of omalizumab
through the use of a challenge model to determine time-dependent inhibition of ragweed-
induced changes in nasal volume as well as correlate the kinetics of omalizumab-induced
decreases in serum free IgE and FcεRI receptors on basophils. METHODS: We conducted a …